Study Examines Link Between GLP-1 Agonists and Cancer Risk

A retrospective study published in the Annals of Oncology reports a 41% decrease in cancer incidence among obese, non-diabetic adults using GLP-1 receptor agonists.

Researchers led by A.A. Kamat analyzed the impact of these weight-loss injections, noting a significant reduction in cancers specifically linked to obesity.

Experts emphasize that further validation is required to determine whether the observed cancer reduction is a direct result of the medication or secondary to weight loss.